CureVac (NASDAQ:CVAC) Sets New 52-Week High - Should You Buy?

CureVac (NASDAQ:CVAC - Get Free Report)'s stock price reached a new 52-week high during trading on Friday . The stock traded as high as $5.72 and last traded at $5.60, with a volume of 22916470 shares. The stock had previously closed at $4.07.

Analysts Set New Price Targets

A number of brokerages have weighed in on CVAC. UBS Group cut their price objective on shares of CureVac from $13.00 to $12.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Jefferies Financial Group restated a "hold" rating and issued a $5.00 price target (down previously from $7.00) on shares of CureVac in a research note on Friday. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $10.00 price objective on shares of CureVac in a research report on Wednesday, May 28th.

CureVac Trading Down 0.5%

The stock has a market cap of $1.25 billion, a PE ratio of 10.13 and a beta of 2.49. The firm has a 50-day moving average price of $3.70 and a 200-day moving average price of $3.46. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20.

CureVac (NASDAQ:CVAC - Get Free Report) last posted its quarterly earnings results on Thursday, May 22nd. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.08). The business had revenue of $0.94 million during the quarter, compared to analysts' expectations of $4.27 million. CureVac had a return on equity of 21.98% and a net margin of 20.72%. As a group, equities analysts anticipate that CureVac will post 0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Millennium Management LLC grew its position in CureVac by 10.3% in the 1st quarter. Millennium Management LLC now owns 1,816,984 shares of the company's stock worth $5,033,000 after purchasing an additional 169,947 shares during the period. Alyeska Investment Group L.P. boosted its stake in shares of CureVac by 25.0% in the 4th quarter. Alyeska Investment Group L.P. now owns 500,000 shares of the company's stock worth $1,705,000 after buying an additional 100,000 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of CureVac in the first quarter worth $853,000. Geode Capital Management LLC grew its holdings in shares of CureVac by 10.3% in the fourth quarter. Geode Capital Management LLC now owns 241,750 shares of the company's stock worth $824,000 after acquiring an additional 22,491 shares during the period. Finally, Deutsche Bank AG increased its position in CureVac by 35.9% during the first quarter. Deutsche Bank AG now owns 230,813 shares of the company's stock valued at $639,000 after acquiring an additional 60,941 shares during the last quarter. 17.26% of the stock is owned by hedge funds and other institutional investors.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.